# Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

> **NCT03349177** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Zhiyong Yu** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer
- Pathological Complete Response
- Neoadjuvant Chemotherapy

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Fluorouracil
- **DRUG:** Docetaxel
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03349177
- **Lead sponsor:** Zhiyong Yu
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-27
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349177, "Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03349177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*